Anthony Letai, MD, PhD, Sworn in as New NCI Director
Anthony Letai, MD, PhD, was sworn in on September 29 as Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), by Health and Human Services Secretary Robert F. Kennedy, Jr.
FDA Removes Vandetanib REMS Program
On September 25, the U.S. Food and Drug Administration (FDA) removed the Risk Evaluation and Mitigation Strategies (REMS) program for vandetanib, according to an announcement from the agency.
$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening
The University of California, Los Angeles (UCLA) and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening and reducing unnecessary callbacks and anxiety for patients.
Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease
A new clinical trial found that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation compared with radiation alone.
Addition of Xevinapant to Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck
In a phase III trial (TrilynX) reported in the Journal of Clinical Oncology, Bourhis et al found that the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) to platinum-based chemoradiotherapy did not improve event-free survival in patients with unresected locally advanced squamous cell carcinoma of the head and neck.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
More Top Stories
James R. Doty, MD, Pioneer in Neurosurgical Innovation and the Scientific Study of Compassion, Dies at 69
James R. Doty, MD James R. Doty, MD, Clinical Professor of Neurosurgery at Stanford University and a pioneer in both neurosurgical innovation and the scientific study of compassion, died on July 16, 2025. He was 69. Dr. Doty’s death occurred after prolonged hospitalization for medical...
Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer
Adjuvant radiation therapy following radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings from the phase III randomized BART trial presented at the American Society for Radiation Oncology...
ASCO Remembers Past President Harvey M. Golomb, MD, FASCO
ASCO is deeply saddened by the loss of past president Harvey M. Golomb, MD, FASCO, a pioneer in the study of interferon as cancer treatment. Dr. Golomb passed away on August 20, 2025; he was 82. From the beginning of his medical career, Dr. Golomb was a committed member of ASCO. He joined the...
New NIH-Funded Study Identifies Urine-Based Assay for Prostate Cancer
Researchers have developed a novel method to test for prostate cancer using biomarkers present in urine. This approach may significantly reduce the need for invasive, often painful biopsies, the researchers said in a statement. The study, which was funded in part by the National Institutes of...
PAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide
Assessment with a genomic test could help predict which patients with recurrent prostate cancer are most likely to benefit from the addition of hormonal therapy to radiation following prostatectomy, according to findings from the phase II BALANCE trial (NRG GU006) presented in a press briefing...
ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR
ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The ASCO-sponsored TAPUR study is a...
Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease
A new clinical trial found that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation compared with radiation alone. The phase II LUNAR trial is the...
